• Dyne Therapeutics plans to raise USD 300 million in an underwritten public offering of common stock.
• It also plans to give underwriters a 30-day option to buy up to an additional USD 45 million of shares.
• The offering is subject to market conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.